Search Results
Dec 09, 2025, 09:49 ET 메나리니 그룹, 2025 샌안토니오 유방암 심포지엄에서 엘라세스트란트(ORSERDU)®의 ER+, HER2- 전이성 유방암(mBC) 환자 대상 2상 병용 요법 데이터 발표
발표될 ELEVATE 데이터는 엘라세스트란트를 에베로리무스 또는 아베마시클립과 병용했을 때, ER+/HER2- mBC 환자 중 내분비 치료(ET)에서 질병이 진행된 환자(이전 CDK4/6 억제제 치료 경험 여부와 무관)에서 ESR1 돌연변이 여부와 무관하게 일관된 PFS 혜택이 나타났다. 이번 업데이트된 결과는 또한 병용 요법이 각 표적 치료제와 표준 내분비 치료제 요법의 알려진 안전성 프로파일과 일치함을 보여준다.2상 연구 mPFS(개월, 95% 신뢰구간): 전체 환자 및 하위군
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 07:44 ET Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
patients with relapsed/refractory multiple myeloma who have received 1–3 prior lines of therapy. The primary endpoint is progression-free survival (PFS) and secondary endpoints include complete response or better (≥CR), overall response rate, minimal residual disease (MRD)-negativity (10⁻⁵ by next-generation
More news about: Johnson & Johnson
Dec 09, 2025, 07:30 ET Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
median follow-up of 28.1 months, the primary endpoint of IRC-assessed progression-free survival (PFS) was significantly improved with pirtobrutinib compared to BR (HR=0.20 [95% CI, 0.11–0.37]; p<0.0001). PFS results favored pirtobrutinib across all pre‑specified subgroups, including those with high-risk
More news about: Eli Lilly and Company
Dec 09, 2025, 05:00 ET Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
PTCL) achieved an objective response rate (ORR) of 53.8% and a complete response (CR) rate of 46.1%. Median progression-free survival (PFS) was 37.9 months and the 2-year PFS rate was 58.3%. The research findings validated golidocitinib's long-lasting efficacy and tolerability in the U.S. patient population.
More news about: Dizal Pharmaceutical
Dec 08, 2025, 21:02 ET Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia
control group.The ivonescimab-based regimen met the primary PFS endpoint versus the tislelizumab-based regimen, delivering a decisive, strongly positive outcome with both statistical significance and clear clinical benefit. PFS was substantially prolonged with ivonescimab plus chemotherapy compared
More news about: Akeso, Inc.
Dec 08, 2025, 14:47 ET Menarini Group präsentiert Daten zur Phase-2-Kombination von Elacestrant (ORSERDU®) bei Patientinnen mit ER+, HER2- metastasiertem Brustkrebs (mBC) auf dem San Antonio Breast Cancer Symposium 2025
beobachtet."Die ELEVATE-Daten, die auf der SABCS vorgestellt werden, zeigen, dass Elacestrant in Kombination mit Everolimus oder Abemaciclib einen konsistenten PFS-Vorteil zeigt, unabhängig vom ESR1 Mutationsstatus bei Patientinnen mit ER+/HER2- mBC, die unter endokriner Therapie (ET) einen Krankheitsfortschritt
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:41 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
observed."The ELEVATE data to be presented at SABCS demonstrate that elacestrant in combination with everolimus or with abemaciclib shows a consistent PFS benefit, irrespective of ESR1 mutation status in patients with ER+/HER2- mBC, who experience disease progression on endocrine therapy (ET), with
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:30 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
observed."The ELEVATE data to be presented at SABCS demonstrate that elacestrant in combination with everolimus or with abemaciclib shows a consistent PFS benefit, irrespective of ESR1 mutation status in patients with ER+/HER2- mBC, who experience disease progression on endocrine therapy (ET), with
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 07, 2025, 21:00 ET Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
clinical benefit.Across the 400–1200 μg/kg range, the 12-month PFS rate was 61.2% (median follow-up: 9.6 months). At 400 μg/kg (n=11), median follow-up reached 13.1 months, with a 12-month PFS rate of 56.8%.Executive CommentaryDr. Charles
More news about: Leads Biolabs
Dec 07, 2025, 20:57 ET IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
had R-ISS stage III with a triple-hit. 4 patients had extramedullary disease.With a median follow-up of 27.04 months, the median PFS was not reached. The PFS rates at 12, 18 and 24 months were 87.5%, 80.2% and 74.5%, respectively. All patients achieved MRD negativity within 1 month, and 80% of
More news about: IASO Bio
Dec 07, 2025, 16:30 ET Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
months, respectively. Among all subgroups, the largest PFS effect size was observed in the treatment-naïve subgroup, which had the longest follow-up at this data cut, with a 76% reduction in the risk of disease progression or death. A formal PFS analysis testing for superiority is planned at a future
More news about: Eli Lilly and Company
Dec 07, 2025, 07:30 ET Studies Point to a Growing Role for New Therapies and Immunotherapies in Treating Blood Cancers
as well, showing 18-month progression-free survival (PFS) rates of 86.9% in the pirtobrutinib arm and 82.3% in the ibrutinib arm. Preliminary results suggest treatment-naive participants saw the most pronounced benefit for this endpoint."The PFS is still a little bit immature at this point, but
More news about: American Society of Hematology
Dec 06, 2025, 09:30 ET Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
CARVYKTI® as early as second line and 59 of those patients had standard-risk cytogenetics.1 At a median follow-up of 33.6 months, the 30-month PFS rate among the standard-risk patients in the as-treated population appeared to plateau at 80.5 percent (95 percent CI, 67.2–88.8) following a single
More news about: Johnson & Johnson
Dec 05, 2025, 16:20 ET Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high one-year disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) rates in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, papillary-only non-muscle invasive bladder
More news about: Johnson & Johnson
Dec 03, 2025, 12:59 ET U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
doses. This trial's primary endpoint is progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria, as assessed by blinded independent review committee (IRC). Secondary endpoints include PFS, as assessed by investigator; overall response rate (ORR) and
More news about: Eli Lilly and Company
Dec 03, 2025, 07:30 ET ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
approved dosing of glofitamab). Primary endpoints of the study include safety and tolerability. Secondary efficacy endpoints include ORR, DOR, CRR, PFS, RFS, and OS as well as pharmacokinetics and immunogenicity.For more information about the LOTIS-7 trial, visit
More news about: ADC Therapeutics SA
Dec 02, 2025, 16:05 ET ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
consistent with or different from the LOTIS-7 data presented at EHA and ICML and future regulatory and compendia strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval for ZYNLONTA®; future safety and efficacy results of the Phase 2 IIT
More news about: ADC Therapeutics SA
Dec 02, 2025, 16:05 ET Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
plus tislelizumab and chemotherapy demonstrated highly statistically significant and clinically meaningful improvements in progression-free survival (PFS) compared to the control arm, trastuzumab plus chemotherapy. Ziihera plus tislelizumab and chemotherapy also demonstrated clinically meaningful
More news about: Jazz Pharmaceuticals plc
Dec 02, 2025, 08:15 ET AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
combination with R2 for patients with relapsed or refractory (R/R) FL (n=243) demonstrate significantly superior progression-free survival (PFS) and overall response rates (ORR) compared to standard of care R2 (n=245).1The study showed that treatment with epcoritamab
More news about: AbbVie Inc.
Dec 02, 2025, 06:42 ET Prefilled Syringes (PFS) Market Size to Grow USD 32.98 Billion by 2035 at a CAGR 13.75 | Vantage Market Research
disease management & wearable injectorsRising contamination concerns encouraging pharma to shift toward closed-system PFSStrong governmental demand for PFS-based vaccination programsAutomation & robotics in fill–finish enabling scale expansion and cost competitivenessTechnology
More news about: Vantage Market Research
Dec 01, 2025, 17:31 ET Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight
such as FOLFOX (5-FU/LV/oxaliplatin) and FOLFIRI (5-FU/LV/irinotecan), yield higher response rates, improved progression-free survival (PFS), and better overall outcomes compared to 5-FU/LV alone. For patients who no longer respond to FOLFOX or CAPEOX, second-line therapy typically involves
More news about: DelveInsight Business Research, LLP
Dec 01, 2025, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
consistent with or different from the LOTIS-7 data presented at EHA and ICML and future regulatory and compendia strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval for ZYNLONTA®; future safety and efficacy results of the Phase 2 IIT in MZL and
More news about: ADC Therapeutics SA
Dec 01, 2025, 06:30 ET Denison & Ya'thi Néné Lands and Resources Announce Signing of the Nuhenéné Benefit Agreement with Three First Nations and Four Municipalities
feasibility study was completed for the Phoenix deposit as an ISR mining operation, and an update to the previously prepared 2018 Pre-Feasibility Study ('PFS') was completed for Wheeler River's Gryphon deposit as a conventional underground mining operation. Based on the respective studies, both deposits have
More news about: Denison Mines Corp.
Dec 01, 2025, 06:00 ET Thesis Gold Announces Positive Prefeasibility Study for Lawyers-Ranch Project: After-Tax NPV5% of $2.37 Billion and 54.4% IRR
announce positive results from an independent Prefeasibility Study ("PFS") for its 100% owned Lawyers-Ranch Project ("Lawyers-Ranch" or the "Project") in the prolific Toodoggone Mining District of British Columbia.The PFS was prepared by Ausenco Engineering Canada ULC. ("Ausenco"), Mining
More news about: Thesis Gold Inc.
Nov 28, 2025, 00:13 ET The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
and the disease control rate was 71%. Median DOR was not reached, and the 12-month probability of sustained response was 53%. Median PFS was 5.5 months, with 12-month PFS rate was 29%. Safety with sac-TMT was manageable, the most frequent grade 3 or 4 treatment-related adverse events (AEs) (≥5%) were hematologic
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.